Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warns Industry: We’re Looking ‘Closely And More In-Depth At Class II Recalls’

Also: Troubles with production and process controls at the heart of most class II’s, agency analysis reveals

Executive Summary

The US FDA says it’s keeping a sharp eye on medical device manufacturers that initiate the moderate-risk recalls – especially firms that trigger multiple class II’s in a given year.

You may also be interested in...



More Headaches For Philips As FDA Labels Another Ventilator Recall As High-Risk Class I

The recalled vents are designed to provide high-flow therapy to patients, but problems can crop up “if the system pressure reaches the default maximum limit,” the US agency says. The recall is more bad news for Philips, which recently initiated a separate class I recall of certain breathing and ventilator devices.

New FDA Webform Makes It Easier For Device Makers To Report Shortages

The US agency on 3 August said the webform should be used by manufacturers to report shortages of products deemed critical to fighting the ongoing COVID-19 pandemic.

DOJ: Alere Unit Billed Medicare For Diabetic Testing Supplies For The Dead

Alere Medical and its now-defunct subsidiary Arriva Medical will pay the US government $160m to settle allegations that they violated the False Claims Act. It’s the second settlement that Alere has entered into with the Department of Justice in recent weeks.

Topics

UsernamePublicRestriction

Register

MT143949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel